Clinic
Right Care INC
Right Care INC was paid $4.38M by Medicaid between Jan 2018 and Dec 2024, across 36 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 46% of everything it billed.
33Billing provider infoRIGHT CARE INC
COLUMBIA, TN 38401
COLUMBIA, TN 38401
33aNPI1346573540assigned 09/08/2009
33bProvider typePrimary Care Clinic/Center
28Total paid$4.38M
24GClaims150,228
24DCodes billed36
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Primary Care Clinic/Center providers in Tennessee
Rank by total paid#6 of 139
Median peer was paid$101K
This provider vs. median43×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,119 | $509K | |
| 2019 | 20,270 | $565K | |
| 2020 | 14,714 | $430K | |
| 2021 | 20,832 | $683K | |
| 2022 | 29,738 | $869K | |
| 2023 | 28,143 | $796K | |
| 2024incomplete | 19,412 | $523K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 46% | 34,472 | 28,606 | $1.99M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14% | 14,934 | 13,087 | $596K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 11% | 5,561 | 4,926 | $489K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 8.6% | 10,524 | 9,352 | $374K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 5.4% | 24,191 | 10,695 | $237K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 4.0% | 2,892 | 2,644 | $173K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.7% | 9,260 | 7,735 | $163K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.2% | 17,277 | 15,276 | $138K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.4% | 1,506 | 1,238 | $106K |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | <1% | 5,085 | 546 | $24K |
| 87807 | <1% | 1,685 | 1,531 | $12K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 134 | 126 | $10K |
24 more codes
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 103 | $8K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,094 | $8K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 103 | $7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,372 | $6K |
| 81002 | <1% | 3,785 | $6K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,145 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,682 | $3K |
| 81025 | <1% | 639 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 234 | $2K |
| 69210 | <1% | 70 | $2K | |
| 3008F | <1% | 297 | $2K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 25 | $2K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 211 | $2K |
| 3074F | <1% | 173 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 40 | $1K |
| 3078F | <1% | 96 | $710.00 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 28 | $394.98 |
| 3079F | <1% | 61 | $300.00 | |
| 80305 | <1% | 13 | $47.99 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 233 | $23.76 |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 14 | $23.66 |
| 3077F | <1% | 18 | $20.00 | |
| 3061F | 0% | 16 | $0.00 | |
| 99072 | 0% | 255 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, CHANDLER (CEO)